Stock analysis, AI verdict, fundamentals & technical signals
Rating: HOLD
Price: $377.78 Analyst target: $436.46 Upside: 15.53%
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
See the full interactive analysis & chart →Informational only — not investment advice.